All News

RheumNow Podcast square

Trends and Innovations from Barcelona (6.20.2025)

d Jack Cush, MD

Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

Read Article
pregnancy,doctor,consult

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns

d Bella Mehta, MBBS, MS

While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes.

Read Article
epilepsy,brain,seizure,CVA

Striking a ‘nerve’ in RA: understanding neuromodulation

d Janet Pope, MD, MPH, FRCPC

Over the last 50 years, discoveries of connections between inflammation and the nervous system have been better understood.

Read Article
heart in a puzzle

What would it take for JAKs to ROCK the boat?

d David Liew, FRACP

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.

Read Article
light bulb idea

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.

Read Article
ALTO: Long-term Outcomes of APIPPRA Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush RheumNow ( View Tweet)
Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer? As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. https://t.co/HGbXVLVuSC
Dr. John Cush RheumNow ( View Tweet)
Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona. https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF

Links:

Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm

Links:

Dr. John Cush RheumNow ( View Tweet)
DMARD Combinations in RA Treatment Dr. Jiha Lee discusses abstract OP0195 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/lrZRDvWD0z https://t.co/PS4k2bCqet

Links:

Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib's Place in the PsA Treatment Algorithm? Dr. Eric Ruderman offers his perspective on where deucravacitinib will fit in the treatment algorithm and trials presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/6Ozrvr5IMt https://t.co/w7FJs4wir9

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Safety Update Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
Pregnancy outcomes in autoinflammatory disease To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO
Dr. John Cush RheumNow ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow ( View Tweet)
From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow ( View Tweet)
New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX

Links:

Dr. John Cush RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR

Links:

Dr. John Cush RheumNow ( View Tweet)
Which CAR T Cell is Mighty? Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
×